A therapeutic drug, called lenalidomide, has shown improved outcomes and survival rates in patients with a serious type of bone marrow cancer (multiple myeloma), according to a largest of its kind of study. The study published in The Lancet Oncology, show an improvement for those who received ongoing therapy with the drug lenalidomide, compared to those not receiving...Continue Reading

Understanding the proliferation of malignant myeloma cells can only be discerned by going back to the biology of the disease, explained Sundar Jagannath, MD, and greater understanding of a patient’s cytogenetics may compound the success seen with chemotherapy and novel adoptive cellular therapies, such as chimeric antigen receptor (CAR) T-cell therapy. “At the moment, the...Continue Reading